Hightide Therapeutics Inc (HK:2511)
:2511
Want to see HK:2511 full AI Analyst Report?
2511 Stock Chart & Stats
HK$3.05
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$3.05
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.80 - HK$4.72
Previous CloseN/A
Volume82.00K
Average Volume (3M)1.41M
Market Cap
HK$1.57B
Enterprise ValueHK$1.23B
Total Cash (Recent Filing)HK$502.94M
Total Debt (Recent Filing)HK$126.92M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding571,325,700
10 Day Avg. Volume641,080
30 Day Avg. Volume1,410,076
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.14
Price to Sales (P/S)0.00
P/FCF Ratio-7.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.80Price Target Upside90.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$3.00B
Bulls Say, Bears Say
Bulls Say
Balance-sheet ImprovementThe shift to positive equity and a more manageable debt-to-equity (~0.41 in 2025) materially reduces near-term refinancing risk. This stronger capital structure gives management greater flexibility to fund R&D and clinical programs without immediate distressed financing, improving multi-month operational resilience.
Improving Cash-flow TrajectoryAlthough operating and free cash flows remain negative, the step toward a less-negative 2025 free cash flow signals improving cash efficiency or lower discretionary outflows. Sustained improvement can extend runway, reduce frequency of dilutive raises and support continued program funding over the coming quarters.
Clear Therapeutic FocusA concentrated R&D strategy in metabolic disease aligns resources and expertise to a defined market niche. That focus can create durable advantages in trial design, regulatory knowledge and partnerships, improving odds of efficient development and commercialization versus a scattered pipeline over the medium term.
Bears Say
Zero Reported RevenueThe company is pre-revenue with no commercial sales reported across all provided periods, meaning operational viability depends entirely on future clinical success and commercialization. Lack of revenue prevents self-funding and creates ongoing exposure to capital markets and execution risk.
Persistent Net LossesConsistent, sizable operating and net losses erode shareholder equity and imply that break-even is distant absent product revenue. Persistent negative profitability pressures returns on invested capital and increases the likelihood of future fundraising, diluting shareholders and stressing long-term value creation.
Reliance On External FundingOngoing cash burn and reliance on external financing, coupled with the noted increase in debt since 2023, elevate refinancing and dilution risk. If clinical setbacks occur or markets tighten, access to affordable capital could be constrained, threatening program continuity and long-term strategy execution.
Hightide Therapeutics Inc News
2511 FAQ
What was Hightide Therapeutics Inc’s price range in the past 12 months?
Hightide Therapeutics Inc lowest stock price was HK$1.80 and its highest was HK$4.72 in the past 12 months.
What is Hightide Therapeutics Inc’s market cap?
Hightide Therapeutics Inc’s market cap is HK$1.57B.
When is Hightide Therapeutics Inc’s upcoming earnings report date?
Hightide Therapeutics Inc’s upcoming earnings report date is Sep 01, 2026 which is in 86 days.
How were Hightide Therapeutics Inc’s earnings last quarter?
Hightide Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported -HK$0.268 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.268.
Is Hightide Therapeutics Inc overvalued?
According to Wall Street analysts Hightide Therapeutics Inc’s price is currently Undervalued.
Does Hightide Therapeutics Inc pay dividends?
Hightide Therapeutics Inc does not currently pay dividends.
What is Hightide Therapeutics Inc’s EPS estimate?
Hightide Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hightide Therapeutics Inc have?
Hightide Therapeutics Inc has 571,325,700 shares outstanding.
What happened to Hightide Therapeutics Inc’s price movement after its last earnings report?
Hightide Therapeutics Inc reported an EPS of -HK$0.268 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of Hightide Therapeutics Inc?
Currently, no hedge funds are holding shares in HK:2511
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hightide Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$5.80 (90.16% Upside)
HK$5.80 (90.16% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
273.21%
12-Months-Change
Fundamentals
Return on Equity
-39.41%
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Company Description
Hightide Therapeutics Inc
HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs. Its lead product candidate is HTD1801, a gut-liver anti-inflammatory metabolic modulator that targets metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug for the treatment of alcoholic hepatitis; HTD1804 to treat obesity; HTD1805, a multifunctional small molecule drug for the treatment of metabolic diseases; and HTD2802 for the treatment of inflammatory bowel disease. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.
2511 Stock 12 Month Forecast
Average Price Target
HK$5.80
▲(90.16% Upside)
Technical Analysis
CANbridge Pharmaceuticals Inc.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―
Cutia Therapeutics
―
Options Prices
Currently, No data available
---